TCTMD’s Top 10 Most Popular Stories for June 2019
TAVR topics plus the FDA efforts to plumb the mortality signal with paclitaxel-based PAD devices dominated this month’s list.
The US Food and Drug Administration’s deep dive into the mortality signal with paclitaxel-based devices for PAD topped our most popular stories this month, but a range of TAVR stories also made the list—not surprisingly, given the timing of the TVT 2019 meeting. TAVR topics in the top 10 this month included the final Centers for Medicare & Medicaid Services coverage decision, vascular closure postprocedure, concomitant use of non-vitamin K antagonist oral anticoagulants (NOACs), operator requirements, and undertreatment of aortic stenosis. The outlier for June 2019: a story carried over from the European Atherosclerosis Society meeting looking at whether or not to measure and treat lipoprotein(a).
The 2-day meeting of the Circulatory System Devices Panel was expected to debate next steps and possible regulatory actions.
The data are a mess, and more uniformity is needed in clinical trials going forward. So concluded some “inconclusive” debate.
A debate at SCAI delved into contemporary TAVR practice and whether the mandate to involve surgeons remains necessary.
The agency’s advisory committee grilled the agency and sponsors on their data, while emphasizing practicalities in treating PAD.
Still, as many as one in four patients are afflicted by vascular complications following TAVR, experts note.
A 6-year registry snapshot hints that TAVR stroke rates have been stable, spurring questions for low-risk patients and brain debris.
After a yearlong review and wide-ranging debate over volume and outcomes, CMS has finalized its stance on TAVR payments.
Researchers debated the merits of lipoprotein(a)—while one sees the future, another argued in favor of sticking with LDL cholesterol.
By one estimate, 65% don’t get referred for aortic valve replacement, posing questions for who and how to track patients with early aortic stenosis.
Bleedings risks were similar with NOACs and vitamin K antagonists in a registry study, but ischemic risks were higher with the newer agents.
TCTMD’s in-depth feature stories this month
The strategy aims to leverage advancements in pharmacology and technology to fundamentally change how A-fib is managed.
Still in question is how much a MitraClip will truly help a patient for whom heart failure is his or her primary problem.